HRP970242A2 - Inhibition of matrix metalloproteases by 2-(omega-aroylalkyl)-4-biaryl-oxobutric acids - Google Patents

Inhibition of matrix metalloproteases by 2-(omega-aroylalkyl)-4-biaryl-oxobutric acids

Info

Publication number
HRP970242A2
HRP970242A2 HR08/645,029A HRP970242A HRP970242A2 HR P970242 A2 HRP970242 A2 HR P970242A2 HR P970242 A HRP970242 A HR P970242A HR P970242 A2 HRP970242 A2 HR P970242A2
Authority
HR
Croatia
Prior art keywords
oxobutric
aroylalkyl
biaryl
omega
inhibition
Prior art date
Application number
HR08/645,029A
Other languages
English (en)
Inventor
William J Scott
Margaret A Popp
David S Hartsough
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of HRP970242A2 publication Critical patent/HRP970242A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/004—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46—Friedel-Crafts reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/63—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/80—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/88—Unsaturated compounds containing keto groups containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR08/645,029A 1996-05-15 1997-05-09 Inhibition of matrix metalloproteases by 2-(omega-aroylalkyl)-4-biaryl-oxobutric acids HRP970242A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64502996A 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
HRP970242A2 true HRP970242A2 (en) 1998-04-30

Family

ID=24587374

Family Applications (1)

Application Number Title Priority Date Filing Date
HR08/645,029A HRP970242A2 (en) 1996-05-15 1997-05-09 Inhibition of matrix metalloproteases by 2-(omega-aroylalkyl)-4-biaryl-oxobutric acids

Country Status (22)

Country Link
EP (1) EP0904260B1 (de)
JP (1) JP3524556B2 (de)
CN (1) CN1119313C (de)
AR (1) AR007099A1 (de)
AT (1) ATE224350T1 (de)
AU (1) AU715877B2 (de)
BR (1) BR9709078A (de)
CA (1) CA2254750C (de)
CO (1) CO5011071A1 (de)
DE (1) DE69715619T2 (de)
ES (1) ES2184092T3 (de)
HN (1) HN1997000070A (de)
HR (1) HRP970242A2 (de)
ID (1) ID17938A (de)
PA (1) PA8429601A1 (de)
PE (1) PE66198A1 (de)
SV (1) SV1997000038A (de)
TN (1) TNSN97081A1 (de)
TW (1) TW457231B (de)
WO (1) WO1997043240A1 (de)
YU (1) YU18397A (de)
ZA (1) ZA974028B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5011061A1 (es) 1996-05-15 2001-02-28 Bayer Corp Inhibicion de las metaloprotesas de matriz por acidos biariloxobutiricos sustituidos y composiciones farmaceuticas que los contienen
TNSN97086A1 (fr) 1996-05-15 2005-03-15 Bayer Corp La substitution des acides derivatives 4-albutyrique comme inhibiteurs de la matrice metalloprotease.
TNSN97082A1 (fr) 1996-05-15 2005-03-15 Bayer Corp Inhibition des matrices metalloproteases par la substitution des composes phenetyles
CO4990925A1 (es) 1996-05-15 2000-12-26 Bayer Corp Acidos oxibutiricos sustituidos como inhibidores de la metaloproteasa de matriz
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
EP1031349A1 (de) * 1999-02-25 2000-08-30 Bayer Aktiengesellschaft Verwendung von substituierten 4-Biarylbuttersäuren und 5-Biarylpentansäuren zur Behandlung von zerebralen Krankheiten
US20170022171A1 (en) 2014-04-03 2017-01-26 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentanecarboxylic acids and their use
US20170119776A1 (en) 2014-04-03 2017-05-04 Bayer Pharma Aktiengesellschaft Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof
CA2944614A1 (en) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases
CN116687925B (zh) * 2022-11-04 2024-10-22 中国科学院遗传与发育生物学研究所 一种侵蚀性蛋白酶抑制剂及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS243570B1 (en) * 1984-08-31 1986-06-12 Miroslav Kuchar Omega-aryloxoalkane acids
GB9101468D0 (en) * 1991-01-23 1991-03-06 Ciba Geigy Coating compositions
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors

Also Published As

Publication number Publication date
AR007099A1 (es) 1999-10-13
AU3010497A (en) 1997-12-05
DE69715619T2 (de) 2003-01-16
ZA974028B (en) 1998-02-19
CO5011071A1 (es) 2001-02-28
YU18397A (en) 1999-11-22
PE66198A1 (es) 1998-10-23
HN1997000070A (es) 1997-09-08
JP3524556B2 (ja) 2004-05-10
CA2254750A1 (en) 1997-11-20
ID17938A (id) 1998-02-12
ES2184092T3 (es) 2003-04-01
AU715877B2 (en) 2000-02-10
DE69715619D1 (de) 2002-10-24
TW457231B (en) 2001-10-01
ATE224350T1 (de) 2002-10-15
CN1119313C (zh) 2003-08-27
WO1997043240A1 (en) 1997-11-20
EP0904260B1 (de) 2002-09-18
SV1997000038A (es) 1998-09-01
EP0904260A1 (de) 1999-03-31
CN1234791A (zh) 1999-11-10
BR9709078A (pt) 1999-08-03
PA8429601A1 (es) 2000-05-24
TNSN97081A1 (fr) 2005-03-15
JP2001509783A (ja) 2001-07-24
CA2254750C (en) 2003-09-30

Similar Documents

Publication Publication Date Title
EP1004669A4 (de) Neuer hemmer der differentierung
ZA975675B (en) Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one
PL331254A1 (en) Phosphonianic inhibitors of matrix metaloproteases
ZA959948B (en) Matrix metalloprotease inhibitors
DE69533256D1 (en) Chimäre komplement inhibitor proteine
PL339660A1 (en) Derivatives of amidocarboxylic acids
IL138711A0 (en) Substituted indolealkanoic acids
IL135574A0 (en) Substituted 4-amino-thiazol-2-yl compounds as cdk inhibitors
BR9612707A (pt) Composiç o detergente compreendendo uma enzima pectinesterase
HRP970244A2 (en) Inhibition of matrix metalloproteases by 2-substituent-4-(substituted phenyl)-4-oxobutric acids
IL137162A0 (en) 2,3,4,5-tetrahydro -1h- [1,4]-benzodiazepine -3- hydroxamic acids as matrix metalloproteinase inhibitors
EP0913404A4 (de) Differenzierungsinhibitor
HRP970242A2 (en) Inhibition of matrix metalloproteases by 2-(omega-aroylalkyl)-4-biaryl-oxobutric acids
HUP9904664A3 (en) Substituted 4-biphenyl-4-hydroxybutyric acid derivatives as matrix metalloprotease inhibitors
IL115995A0 (en) Substituted 4-biarylbutyric or 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors
SG52778A1 (en) Saccharin derivative proteolytic enzyme inhibitors
HRP970243B1 (en) Inhibition of matrix metalloproteases by substituted phenethyl compounds
HRP970247A2 (en) Substituted 4-arylbutric acid derivatives as matrix metalloprotease inhibitors
PL339759A1 (en) Method of obtaining substituted 4-phenyl-4-cyanohexanic acids
HRP970246A2 (en) Substituted oxobutric acids as matrix metalloprotease inhibitors
PL316303A1 (en) Derivatives of 2-(4-pyrazplyloxy-pyrimidin-5yl)-acetic acid
ZA939480B (en) Enzyme inhibitor
SG49610A1 (en) Novel inhibitor
HUP9901345A3 (en) Novel quinoxaline- and quinoxalinylalkane-phosphonic acids
GB9406559D0 (en) Novel enzyme inhibition

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20030506

Year of fee payment: 7

ODBC Application rejected